Literature DB >> 26082944

Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis.

Young-Ho Lee1, David K Ann1.   

Abstract

Epigenetics in cancer prognosis and therapy is gaining recognition in recent years. Breast cancer is a genetic disease harboring numerous genetic mutations, including tumor suppressor BRCA1 and BRCA2 mutations. However, the functions of BRCA1 in cancer cells are also altered by non-genetic mechanisms, including DNA methylation and chromatin structure. Therefore, identification of epigenetic markers for breast cancer is very important for early diagnosis and effective therapy. This review focuses on recent findings on the roles of Heterochromatin protein 1 (HP1) in BRCA1 functions and breast cancer progression. We previously showed that BRCA1 function and breast cancer progression are frequently associated with HP1 expression level and potentially with chromatin structure. Herein, we suggest that bi-phasic expression of HP1 during breast cancer progression indicates dual roles of HP1 in tumorigenesis. Exploiting differential HP1 expression in tumors could lead to effective cancer therapy. Re-setting the chromatin structure may be a critical step for high-efficiency cancer therapy for many breast cancer patients.

Entities:  

Keywords:  BRCA1; Epigenetics; HP1; PARP inhibitor; biomarker; breast cancer

Year:  2015        PMID: 26082944      PMCID: PMC4465567     

Source DB:  PubMed          Journal:  J Nat Sci        ISSN: 2377-2700


  40 in total

Review 1.  Epigenetic therapy of cancer: past, present and future.

Authors:  Christine B Yoo; Peter A Jones
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

2.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.

Authors:  Stefan Kubicek; Roderick J O'Sullivan; E Michael August; Eugene R Hickey; Qiang Zhang; Miguel L Teodoro; Stephen Rea; Karl Mechtler; Jennifer A Kowalski; Carol Ann Homon; Terence A Kelly; Thomas Jenuwein
Journal:  Mol Cell       Date:  2007-02-09       Impact factor: 17.970

3.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

4.  Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9.

Authors:  Dorothea Greiner; Tiziana Bonaldi; Ragnhild Eskeland; Ernst Roemer; Axel Imhof
Journal:  Nat Chem Biol       Date:  2005-07-17       Impact factor: 15.040

5.  Evidence for the existence of an HP1-mediated subcode within the histone code.

Authors:  Gwen Lomberk; Debora Bensi; Martín E Fernandez-Zapico; Raul Urrutia
Journal:  Nat Cell Biol       Date:  2006-03-12       Impact factor: 28.824

6.  The histone subcode: poly(ADP-ribose) polymerase-1 (Parp-1) and Parp-2 control cell differentiation by regulating the transcriptional intermediary factor TIF1beta and the heterochromatin protein HP1alpha.

Authors:  Delphine Quénet; Véronique Gasser; Laetitia Fouillen; Florence Cammas; Sarah Sanglier-Cianferani; Régine Losson; Françoise Dantzer
Journal:  FASEB J       Date:  2008-08-01       Impact factor: 5.191

7.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

Review 8.  Genetic and epigenetic aspects of breast cancer progression and therapy.

Authors:  Shannon Byler; Sarah Goldgar; Sarah Heerboth; Meghan Leary; Genevieve Housman; Kimberly Moulton; Sibaji Sarkar
Journal:  Anticancer Res       Date:  2014-03       Impact factor: 2.480

Review 9.  Epigenetics in breast cancer: what's new?

Authors:  Yi Huang; Shweta Nayak; Rachel Jankowitz; Nancy E Davidson; Steffi Oesterreich
Journal:  Breast Cancer Res       Date:  2011-11-01       Impact factor: 6.466

10.  BRCA1 foci in normal S-phase nuclei are linked to interphase centromeres and replication of pericentric heterochromatin.

Authors:  Gayle J Pageau; Jeanne B Lawrence
Journal:  J Cell Biol       Date:  2006-12-04       Impact factor: 10.539

View more
  7 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

2.  The mouse HP1 proteins are essential for preventing liver tumorigenesis.

Authors:  Nehmé Saksouk; Shefqet Hajdari; Yannick Perez; Marine Pratlong; Célia Barrachina; Céline Graber; Damien Grégoire; Aliki Zavoriti; Amélie Sarrazin; Nelly Pirot; Jean-Yohan Noël; Lakhdar Khellaf; Eric Fabbrizio; Eric Julien; Florence M Cammas
Journal:  Oncogene       Date:  2020-02-04       Impact factor: 9.867

3.  A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression.

Authors:  C Chang; J Liu; W He; M Qu; X Huang; Y Deng; L Shen; X Zhao; H Guo; J Jiang; X Y Fu; R Huang; D Zhang; J Yan
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

5.  Contribution of promoter DNA sequence to heterochromatin formation velocity and memory of gene repression in mouse embryo fibroblasts.

Authors:  Patricia A Vignaux; Celyn Bregio; Nathaniel A Hathaway
Journal:  PLoS One       Date:  2019-07-03       Impact factor: 3.240

6.  HP1a-mediated heterochromatin formation inhibits high dietary sugar-induced tumor progression.

Authors:  Che-Wei Chang; Yu-Chia Shen; Shian-Jang Yan
Journal:  Cell Death Dis       Date:  2021-12-06       Impact factor: 8.469

7.  Downregulation of HP1α suppresses proliferation of cholangiocarcinoma by restoring SFRP1 expression.

Authors:  Wenlong Cheng; Li Tian; Bing Wang; Yongqiang Qi; Wenhua Huang; Hongbo Li; Yong-Jun Chen
Journal:  Oncotarget       Date:  2016-07-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.